Epicardially Placed Bioengineered Cardiomyocyte Xenograft in Immune-Competent Rat Model of Heart Failure.

Autor: Chinyere IR; Sarver Heart Center, University of Arizona, Tucson, AZ, USA., Bradley P; Sarver Heart Center, University of Arizona, Tucson, AZ, USA., Uhlorn J; Physiological Sciences GIDP, University of Arizona, Tucson, AZ, USA., Eason J; Sarver Heart Center, University of Arizona, Tucson, AZ, USA., Mohran S; Department of Biomedical Engineering, University of Arizona, Tucson, AZ, USA., Repetti GG; Sarver Heart Center, University of Arizona, Tucson, AZ, USA., Daugherty S; Sarver Heart Center, University of Arizona, Tucson, AZ, USA., Koevary JW; Department of Biomedical Engineering, University of Arizona, Tucson, AZ, USA., Goldman S; Sarver Heart Center, University of Arizona, Tucson, AZ, USA., Lancaster JJ; Sarver Heart Center, University of Arizona, Tucson, AZ, USA.
Jazyk: angličtina
Zdroj: Stem cells international [Stem Cells Int] 2021 Jul 24; Vol. 2021, pp. 9935679. Date of Electronic Publication: 2021 Jul 24 (Print Publication: 2021).
DOI: 10.1155/2021/9935679
Abstrakt: Background: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are under preclinical investigation as a cell-based therapy for heart failure post-myocardial infarction. In a previous study, tissue-engineered cardiac grafts were found to improve hosts' cardiac electrical and mechanical functions. However, the durability of effect, immune response, and in vitro properties of the tissue graft remained uncharacterized. This present study is aimed at confirming the graft therapeutic efficacy in an immune-competent chronic heart failure (CHF) model and providing evaluation of the in vitro properties of the tissue graft.
Methods: hiPSC-CMs and human dermal fibroblasts were cultured into a synthetic bioabsorbable scaffold. The engineered grafts underwent epicardial implantation in infarcted immune-competent male Sprague-Dawley rats. Plasma samples were collected throughout the study to quantify antibody titers. At the study endpoint, all cohorts underwent echocardiographic, hemodynamic, electrophysiologic, and histopathologic assessments.
Results: The epicardially placed tissue graft therapy improved ( p < 0.05) in vivo and ex vivo cardiac function compared to the untreated CHF cohort. Total IgM and IgG increased for both the untreated and graft-treated CHF cohorts. An immune response to the grafts was detected after seven days in graft-treated CHF rats only. In vitro , engineered grafts exhibited responsiveness to beta-adrenergic receptor agonism/antagonism and SERCA inhibition and elicited complex molecular profiles.
Conclusions: This hiPSC-CM-derived cardiac graft improved systolic and diastolic cardiac function in immune-competent CHF rats. The improvements were detectable at seven weeks post-graft implantation despite an antibody response beginning at week one and peaking at week three. This suggests that non-integrating cell-based therapy delivered by a bioengineered tissue graft for ischemic cardiomyopathy is a viable treatment option.
Competing Interests: The work outlined in this report was the basis for forming the commercial entity Avery Therapeutics, Inc. Drs. Goldman, Koevary, Lancaster, and Ms. Sherry Daugherty have disclosed a financial interest in Avery Therapeutics to the University of Arizona. In addition, the University of Arizona has a financial interest in Avery Therapeutics. These interests have been reviewed and are being managed by the University of Arizona in accordance with its policies on outside interests. All other authors have no relevant conflicts to disclose.
(Copyright © 2021 Ikeotunye Royal Chinyere et al.)
Databáze: MEDLINE
Externí odkaz: